Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin for bladder emptying problems in women with multiple sclerosis
NL-OMON47090Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of silodosin in multiple sclerosis (MS) and neurogenic bladder (2 arms), sponsored by Erasmus MC. Primary endpoint: Residual urine at 6 weeks. Started Feb 2016; status: recruiting.
02
Drugs
silodosin
03
Conditions
multiple sclerosis (MS)neurogenic bladder
Beyond the preview
Go deeper on NL-OMON47090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47090.